Skip to Content

Frequently Searched

Supported by

Perspectives: Published Editorials and Industry Updates

Welcome to Perspectives, our blog designed to keep members, oncology stakeholders, and anyone interested in enhancing the care experience for oncology patients informed on critical issues. You’ll hear from thought leaders and learn about the impact and benefits of medically integrated pharmacy, operational insights designed to support you in the day-to-day delivery of care, as well as timely industry issues facing oncology pharmacy professionals.

SORT

Serving Those Who Served: Delivering Oncology Care to Veterans

What does oncology care look like within the VA system—and how does it differ from the private sector? We recently sat down with former VA oncology pharmacist Nigina Ali, PharmD, to explore how care teams support Veterans through cancer treatment, the unique challenges they face, and the systems in place to meet their needs. Her firsthand insights shed light on both the strengths and the hurdles of delivering high-quality cancer care to those who served.

NCODA Perspective: Protecting Access to Oncology-Optimized Limited Distribution Drugs 

June 26, 2025
Access to oncology-optimized limited distribution (OOLD) drugs is being increasingly threatened by shifting pharmacy benefit manager (PBM) practices that divert prescriptions away from medically integrated pharmacies (MIPs). NCODA is working with stakeholders to defend MIP access and safeguard oncology patients’ treatment journeys.

Coming Soon: Important OCE/IVE Updates

OCE and IVE sheets will soon be known as Patient Education Sheets — clearer, more consistent, and still rooted in the expert-backed information you rely on.

NCODA Announces “Oncology Optimized Limited Distribution” to Bring Clarity and Enhance Patient-Centered Cancer Care Delivery 

May 14, 2025
Cazenovia, New York, May 14, 2025 – During the recent NCODA International Spring Forum, the organization announced the formal definition of Oncology Optimized Limited Distribution (OOLD) to bring clarity to the broadly used term “limited distribution networks “(LDNs), within the oncology ecosystem. This effort supports the improved delivery of oral oncolytics and enhances patient outcomes by promoting medically integrated pharmacy models whenever possible. 

NCODA AT 10 

April 22, 2025
This article is about the founding and evolution of NCODA, sparked by the growing need for better oral oncolytic care, and how the organization has continued to adapt, innovate, and stay true to its patient-centered, collaborative mission over the past decade.

OncolyticsToday: Measuring the Economic Value of Pharmacogenomics in Oncology

April 22, 2025
This article highlights the economic potential of pharmacogenomics (PGx) in precision medicine, particularly in oncology, by demonstrating its ability to improve patient outcomes and reduce costs. It emphasizes the need for more cost-effectiveness studies to support PGx adoption and the benefits of preemptive PGx testing to enhance clinical decision-making and minimize adverse drug reactions.

NCODA Announces Brand Updates, a New Website, and a Future of Innovation and Collaboration 

April 13, 2025
As an organization, NCODA has always been committed to supporting our members in advancing the medically integrated healthcare team and advancing patient care. Today, we are excited to share some important changes that strengthen that commitment and reflect our evolution and focus. We have grown tremendously and are introducing meaningful updates to our brand and our online presence at ncoda.org.